Carles Gil’s research while affiliated with Autonomous University of Barcelona and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (7)


CHIR99021 causes inactivation of Tyrosine Hydroxylase and depletion of dopamine in rat brain striatum
  • Article

October 2023

·

10 Reads

Neuropharmacology

Sally Hamdon

·

Pol Fernandez-Gonzalez

·

Muhammad Yusof Omar

·

[...]

·

Carles Gil

CHIR99021 decreases dopamine content in rat brain striatum through inactivation of Tyrosine Hydroxylase
  • Preprint
  • File available

May 2023

·

26 Reads

CHIR99021, also known as laduviglusib or CT99021, is a Glycogen-synthase kinase 3 α/β inhibitor, which has been reported as a promising drug for cardiomyocyte regeneration or treatment of sensorial hearing loss, among other pathologies. Since the activation of dopamine (DA) receptors regulate dopamine synthesis itself and use glycogen-synthase kinase 3β (GSK3β) as an element in the β-arrestin pathway, we decided to check the effect of GSK3β inhibitors (CHIR99021, SB216763 and lithium ion) in the control of DA synthesis. Using ex vivo experiments with minces from rat brain striatum, we observed that CHIR99021, but not SB216763 nor lithium, causes a complete abrogation of DA synthesis and accumulation, pointing to off-target effects of CHIR99021. This decrease can be attributed to tyrosine hydroxylase (TH) inhibition since the accumulation of L-DOPA in the presence of a DOPA decarboxylase inhibitor was similarly decreased. On the other hand, CHIR99021 caused an exponential increase in the DOPAC / DA ratio, an indicator of DA metabolization, and decreased the incorporation of extracellular DA into striatum minces. In addition, CHIR99021 or SB216763, but not lithium, decreased TH phosphorylation in Ser19. These results demonstrate that CHIR99021 can lead to TH inactivation and DA decrease in brain striatum, opening the possibility of its use in DA-related disorders, and shows effects to be considered in future clinical trials.

Download

Fig. 1. Initially high l-DOPA and [ 3 H]-DA synthesis rates decrease when DA is produced. Brain striatal minces were allowed DA synthesis (A) or not (B) by the timely addition of 100 mM NSD-1015, the decarboxylase inhibitor used to measure l-DOPA synthesis rate (A, B). The results in A were validated using a second method, where minces were incubated with [³H]-tyrosine after a pre-incubation time (C) or from the beginning of the experiment (D) to measure [ 3 H]-DA synthesis rate. Experimental designs are shown as timelines, where "incubation" properly refers to the time period where l-DOPA synthesis from endogenous tyrosine is measured (30 min in A, x axis variable in B) or alternatively [ 3 H]-DA synthesis from 0.12 mM [³H]-tyrosine (10 min in C, x axis variable in D). "Preincubation" refers to the previous time without NSD or [³H]-tyrosine under the same conditions. Data points and the mean ± SEM of 4-5 (A), 6 (B), 4-5 (C) or 5 (D) brain striatal tissue incubations are represented. 100% corresponds to a mean ± SEM of A) 187 ± 17; B) 10 ± 1 pmol l-DOPA/mg h; C) 257,787 ± 42,097 and D) 362,297 ± 38,857 dpm [ 3 H]-DA/mg h. Data in (A, C and D) adjusted well to a one phase exponential decay regression curve (r 2 0.91; 0.98 and 0.97 respectively). *p < 0.05, vs. respective control: A, C) 0 min; B) 30 min, ANOVA plus Dunnett's multiple comparisons test.
Fig. 2. [ 3 H]-DA synthesis rate is controlled by non-stored DA as well as by D 2 -like receptor dependent mechanisms. Increases in intracellular DA were sought by adding increasing concentrations of l-DOPA (A), DA (B) or the VMAT2 inhibitor TBZ (D) to brain striatal minces. In C, either 1 μM DA or the D 2 -like receptor agonist quinpirole were applied, but only quinpirole effects were blocked by the D 2 -like receptor antagonist sulpiride. Experimental designs until measurement are shown as timelines below each graph. Data points and the mean ± SEM of 9-17 (A), 3-18 (B), 4-11(C) and 6-8 (D) brain striatal tissue incubations are represented. In B) 4 incubations were excluded from the analysis after values were considered outliers by the ROUT test. Dose-response curves adjusted to one site competition (A, IC 50 1.6x10 −7 M; r 2 0.95), two-site competition (B, IC 50 9.3x10 −9 M and 5.8x10 −6 M; r 2 0.97; p < 0.005 vs. one-site competition) and one-site competition (D, IC 50 6.1x10 −8 M; r 2 0.96) respectively. 100% corresponds to a mean ± SEM of A) 60,151 ± 4784; B) 295,539 ± 17,413; C) 62,946 ± 2684 and D) 617,245 ± 99,937 dpm [ 3 H]-DA/mg.h. A, B, D). *, p < 0.05, vs. respective control; ANOVA plus Dunnett's multiple comparisons test. C) Two-way ANOVA showed a significant effect of treatment (F(2,34) = 42.2; p < 0.0001) and Sulpiride presence (F(1,34) = 10.4; p < 0.005), and a significant interaction between these two factors (F (2,34) = 4.4 p < 0.05); *, p < 0.05, vs. group without treatment; #, p < 0.05 vs. Quin 100 nM, Two way ANOVA plus Sidak's multiple comparisons test.
Fig. 3. Endogenous DA concentrations increase spontaneously with incubation time if DA synthesis and storage are not impaired. DA accumulated during the incubation of brain striatal minces (A, B, black lines) unless D 2 -like autoreceptors were stimulated with 1 μM quinpirole (A, green line) or the VMAT2 inhibitor TBZ 1 μM (B, blue line) was present. The DOPAC/DA ratio index of DA metabolism increased with TBZ (D), but not with quinpirole (C) treatments or in control conditions (C, D, black lines). The experimental design is shown in the timeline. Data and the means ± SEM of N equal to A) 4 (control), 4 (Quin); B) 6-10 (control), 9-10 (TBZ); C) 3-4 (control), 4 (Quin); D) 5-10 (control), 3-8 (TBZ) brain striatal tissue incubations are represented. In B) 1 and D) 4 incubations were excluded from the analysis after values were considered outliers by the ROUT test. Control curves of DA accumulation (A, B) adjusted to a one-phase association curve (r 2 0.96 and 0.95, respectively) while those of DOPAC/DA ratio (C, D) fit to a linear (r 2 0.81) and a second order polynomial (r 2 0.97) equations, respectively. This latter regression was also followed by Quin in both A) and C) (r 2 0.92 and 0.85, respectively). TBZ effects on D) followed a linear regression (r 2 0.97). Two-way ANOVA showed in A) a significant effect of Treatment (F(1,24) = 81.6; p < 0.0001) and Time (F(3,24) = 32.3; p < 0.0001), and a significant interaction between these two factors (F(3,24) = 15.3 p < 0.0001); in B) a significant effect of Treatment (F(1,85) = 161.3; p < 0.0001) and Time (F (4,85) = 11.8; p < 0.0001), and a significant interaction between these two factors (F(4,85) = 10.1 p < 0.0001); in C) a significant effect of Time (F (3,23) = 16.1; p < 0.0001), and a significant interaction between time and treatment (F(3,23) = 5.5 p < 0.005) and in D) a significant effect of Treatment (F (1,60) = 141.5; p < 0.0001) and Time (F(4,60) = 36.3; p < 0.0001), and a significant interaction between these two factors (F(4,60) = 40.4 p < 0.0001); *p < 0.05, vs. 0 min, ANOVA plus Dunnett's multiple comparisons test; # p < 0.05, vs. data in control curve, ANOVA plus Sidak's multiple comparisons test. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Fig. 4. Endogenous DA vesicular storage and metabolism is altered by exogenous l-DOPA and VMAT2 overexpression. l-DOPA addition to brain striatal minces increased DA concentrations (A) and metabolism (B) while VMAT2 overexpression increased DA storage (C) but decreased DA metabolism (D). Incubation designs are shown as timelines: In A, B) variable incubation times with addition of 1 μM l-DOPA at the beginning of incubation; C-D) no incubation, 30-or 60-min incubation of left or right striatum one month after the injection of AAV-hVMAT2 viral vector unilaterally in the right substantia nigra. Data represent the endogenous DA values and DOPAC/DA ratio and the means ± SEM of N equal to A, B) 4 (control), 3-4 (l-DOPA); C) 13-14 (non-injected), 13-16 (injected); D) 12-15 (noninjected), 12-15 (injected) brain striatal tissue incubations. In B) 1 and C) 5 incubations were excluded from the analysis after values were considered outliers by the ROUT test. Control and l-DOPA curves adjusted to A) a one-phase association curve (r 2 0.89 and 0.97, respectively) and B) linear regression (r 2 0.89 and 0.98, respectively). Two-way ANOVA showed in A) a significant effect of Treatment (F(1,23) = 35.5; p < 0.0001) and Time (F(3,23) = 34.2; p < 0.0001), and a significant interaction between these two factors (F(3,23) = 6.1 p < 0.0001); in B) a significant effect of Treatment (F(1,22) = 112.5; p < 0.0001) and Time (F(3,22) = 99.8; p < 0.0001), and a significant interaction between these two factors (F(3,22) = 21.3 p < 0.0001); in C) a significant effect of Treatment (F (1,65) = 7.8; p < 0.01) and Time (F(2,65) = 15.1; p < 0.0001) without a significant interaction between these factors and in D) a significant effect of Treatment (F(1,78) = 7.1; p < 0.01) and Time (F(2,78) = 11.8; p < 0.0001), without a significant interaction between these factors; *p < 0.05, vs. 0 min, ANOVA plus Dunnett's multiple comparisons test. # p < 0.05, vs. respective control: A, B) data in control curve; C-D) non-injected hemisphere, ANOVA plus Sidak's multiple comparisons test.
Fig. 5. Like DA, endogenous serotonin (5-HT) concentrations also increase spontaneously with incubation time. 5-HT levels in the striatum (A) and hippocampus (B) showed a clear pattern of incubation time-dependent accumulation ex vivo. 0 min bars show non-incubated ice controls. Data represent the endogenous 5-HT values and the means ± SEM of N = 6 brain tissue incubations/group. *p < 0.05, vs. 0 min, # p < 0.05, vs. 120 min; one-way ANOVA plus Tukey's multiple comparisons test.

+1

Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase

April 2022

·

73 Reads

·

6 Citations

Neuropharmacology

Synaptic events are important to define treatment strategies for brain disorders. In the present paper, freshly obtained rat brain striatal minces were incubated under different times and conditions to determine dopamine biosynthesis, storage, and tyrosine hydroxylase phosphorylation. Remarkably, we found that endogenous dopamine spontaneously accumulated during tissue incubation at 37 °C ex vivo while dopamine synthesis simultaneously decreased. We analyzed whether these changes in brain dopamine biosynthesis and storage were linked to dopamine feedback inhibition of its synthesis-limiting enzyme tyrosine hydroxylase. The aromatic-l-amino-acid decarboxylase inhibitor NSD-1015 prevented both effects. As expected, dopamine accumulation was increased with l-DOPA addition or VMAT2-overexpression, and dopamine synthesis decreased further with added dopamine, the VMAT2 inhibitor tetrabenazine or D2 auto-receptor activation with quinpirole, accordingly to the known synaptic effects of these treatments. Phosphorylation activation and inhibition of tyrosine hydroxylase on Ser31 and Ser40 with okadaic acid, Sp-cAMP and PD98059 also exerted the expected effects. However, no clear-cut association was found between dopamine feedback inhibition of its own biosynthesis and changes of tyrosine hydroxylase phosphorylation, assessed by western blot and mass spectrometry. The later technique also revealed a new Thr30 phosphorylation in rat tyrosine hydroxylase. Our methodological assessment of brain dopamine synthesis and storage dynamics ex vivo could be applied to predict the in vivo effects of pharmacological interventions in animal models of dopamine-related disorders.



Analysis of the Function of Receptor Oligomers by Operational Models of Agonism

January 2021

·

125 Reads

·

2 Citations

Evidences from different techniques suggest that GPCRs oligomerize into homo- and hetero-oligomers. Oligomerization adds an extra level of complexity to receptor functionality because the allosteric interactions between protomers modify the intrinsic functional capacity of the single protomers. Reliable mathematical models are needed to quantify and mechanistically explain the observed functional effects. The operational model of agonism of Black and Leff (1983) constitutes a cornerstone in the description of agonism by providing parameter estimates for the pharmacological properties of affinity and efficacy. In the present study we revisit the operational model of agonism through the description of various adaptations and extensions to the model developed in our group. In particular, models for homo- and heterodimer receptors are discussed. Inclusion in the models of constitutive receptor activity and explicit parameters for cooperativity are useful for the interpretation of experimental data. Moreover, these quantitative approaches may clarify complex experimental relationships related to biased signaling. Finally, it is expected that the combined application of mathematical modeling and structural techniques will represent a powerful strategy to identify, visualize and quantify the allosteric interactions responsible for the observed functional effects dependent on receptor aggregation. This information is fundamental in the design and development of drug discovery programs. We believe that further efforts in this field are necessary for the construction of a robust and flexible modern pharmacology.


Structural insights into positive and negative allosteric regulation of a G protein-coupled receptor through protein-lipid interactions

March 2018

·

1,519 Reads

·

43 Citations

Lipids are becoming known as essential allosteric modulators of G protein-coupled receptor (GPCRs). However, how they exert their effects on GPCR conformation at the atomic level is still unclear. In light of recent experimental data, we have performed several long-timescale molecular dynamics (MD) simulations, totalling 24 μs, to rigorously map allosteric modulation and conformational changes in the β2adrenergic receptor (β2AR) that occur as a result of interactions with three different phospholipids. In particular, we identify different sequential mechanisms behind receptor activation and deactivation, respectively, mediated by specific lipid interactions with key receptor regions. We show that net negatively charged lipids stabilize an active-like state of β2AR that is able to dock Gsα protein. Clustering of anionic lipids around the receptor with local distortion of membrane thickness is also apparent. On the other hand, net-neutral zwitterionic lipids inactivate the receptor, generating either fully inactive or intermediate states, with kinetics depending on lipid headgroup charge distribution and hydrophobicity. These chemical differences alter membrane thickness and density, which differentially destabilize the β2AR active state through lateral compression effects.


Citations (3)


... Moreover, due to the role of DA in the control of coordinated movements, alterations in the dopaminergic system also contribute to diseases causing locomotion impairment (Smith-Dijak et al., 2019). Short-term modulation of TH activity includes phosphorylation (Dunkley et al., 2019) and/or end-product feedback inhibition, i.e., by DA itself (González-Sepúlveda et al., 2022). TH is phosphorylated at serine residues Ser8, Ser19, Ser31 and Ser40, according to the rat and mouse sequences, while humans show a Thr in position 8. Humans express four TH isoforms (hTH1-4), derived from a single gene, while most species, including rat, express only one isoform (Lewis et al., 1993). ...

Reference:

CHIR99021 decreases dopamine content in rat brain striatum through inactivation of Tyrosine Hydroxylase
Spontaneous changes in brain striatal dopamine synthesis and storage dynamics ex vivo reveal end-product feedback-inhibition of tyrosine hydroxylase

Neuropharmacology

... Of note, yet in an homodimeric context, an insightful modeling analysis on the asymmetric/symmetric activation of dimeric receptors can be found in [33]. See also [40] for the modeling of the binding and function of a heterodimeric receptor at equilibrium and [14] for an analysis of the function of receptor oligomers by operational models of agonism. ...

Analysis of the Function of Receptor Oligomers by Operational Models of Agonism
  • Citing Chapter
  • January 2021

... The nature of surrounding lipids may also affect GPCR functions and oligomerization, either directly by specific interactions, or indirectly by modification of the environment fluidity [12,13]. For example, studies based on experimental approaches [14,15] or molecular dynamics (MD) simulations [16,17] report that anionic lipids maintain or favor the active state of different receptors. This may affect GPCR responses in various cardiovascular cell types such as cardiomyocytes, endothelium, and vascular smooth muscle cells, which contain anionic lipids [18][19][20][21]. ...

Structural insights into positive and negative allosteric regulation of a G protein-coupled receptor through protein-lipid interactions